Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
This study aims to evaluate the efficacy and safety of telitacicept in the treatment of refractory IgA nephropathy (IgAN).
A retrospective analysis was conducted on 19patients with refractory IgAN, confirmed by renal biopsy and treated with telitacicept (monotherapy or combined with corticosteroids) at the First Hospital of Jilin University between December 2023 and September 2024. Data collected included 24-hour urinary protein excretion (24hUP), serum albumin, estimated glomerular filtration rate (eGFR), and serum creatinine (Scr) at baseline, 1 month, and 3 months after treatment. Adverse events during treatment were recorded. Statistical analysis was performed using SPSS 27.0. Normally distributed continuous data are presented as mean ± standard deviation, and non-normally distributed data as median [interquartile range]. Paired t-tests or Wilcoxon signed-rank tests were used for comparisons before and after treatment, depending on the normality of the data distribution. A P-value < 0.05 was considered statistically significant.
·Proteinuria: Treatment with telitacicept resulted in a rapid and sustained reduction in proteinuria. The median 24hUP decreased from 2.89 [1.68, 4.52] g/d at baseline to 1.11 [0.83, 1.99] g/d at 1 month and further to 0.78 [0.44, 1.11] g/d at 3 months (mean difference = 2.35 g/d, 95% CI: 1.53 to 3.17, P < 0.001), representing a mean reduction rate of 73% from baseline.
· Renal Function: Renal parameters remained stable throughout the observation period. The median eGFR changed from 63.40 [43.50, 111.86] to 63.00 [53.24, 102.64] mL/min/1.73m², while median Scr levels changed from 107.00 [81.00, 166.00] to 111.00 [85.00, 147.00] μmol/L after 3 months of treatment. These changes did not reach statistical significance (P > 0.05).
· Serum Albumin: A significant improvement in serum albumin levels was observed, increasing from 39.30 [35.20, 45.60] g/L at baseline to 44.90 [41.00, 48.00] g/L after 3 months of treatment (P < 0.05).
· Clinical Response: The overall clinical response rate was 89.5%, consisting of complete remission in 2 patients (10.5%) and partial remission in 15 patients (78.9%).
· Safety: Telitacicept demonstrated a favorable safety profile, with no drug-related serious adverse events reported during the follow-up period.
Telitacicept treatment significantly reduces proteinuria and improves serum albumin levels in patients with refractory IgAN while maintaining stable renal function. The high clinical response rate and favorable safety profile support telitacicept as a promising therapeutic option for this challenging patient population.
